Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST With a High Risk for Recurrence: A Randomised Phase III Study
Locations: Addenbrooke’s Hospital, The Beatson West of Scotland Cancer Centre, Royal Marsden Hospital, University College London Hospital, Nottingham City Hospital, Queen Elizabeth Hospital, Weston Park Hospital, The Christie
This study aims to find out whether giving patients adjuvant imatinib for a total of 5 years may prevent some of the GISTs recurring compared to patients who receive adjuvant imatinib for 3 years. GIST patients who have been treated with adjuvant imatinib for 3 years after surgery will be randomly allocated to receive imatinib for 2 more years (Arm A) or to stop imatinib (Arm B). Participants are required to have histologically verified GIST with a high risk of GIST recurrence despite removal of all macroscopic GIST tissue at surgery and 3 years of adjuvant imatinib.
More information can be found at clinicaltrials.gov
To find out more about this trial and whether you could take part, talk to your clinical team.